Impaired sonic hedgehog pathway contributes to cardiac dysfunction in type 1 diabetic mice with myocardial infarction

Qing Xiao1, Ning Hou, Yan-Ping Wang

  • 1Department of Pharmacology, Guangzhou Medical University, Guangzhou 510182, PR China.

Insights

Impaired sonic hedgehog (Shh) signaling contributes to heart dysfunction in type 1 diabetes. Augmenting the Shh pathway improved cardiac function and reduced infarct size in diabetic mice with myocardial infarction.

Area of Science:

  • Cardiovascular Biology
  • Metabolic Disease Research
  • Molecular Signaling Pathways

Background:

  • Diabetes mellitus significantly increases the risk of myocardial infarction (MI) and mortality.
  • The underlying mechanisms linking diabetes to cardiac dysfunction remain incompletely understood.
  • The sonic hedgehog (Shh) signaling pathway plays a role in cardiac development and repair.

Purpose of the Study:

  • To investigate the role of the Shh pathway in cardiac dysfunction in type 1 diabetic mice with MI.
  • To test the hypothesis that an impaired Shh pathway contributes to cardiac dysfunction in this model.

Main Methods:

  • Adult male C57/B6 mice and streptozotocin-induced type 1 diabetic mice were utilized.
  • Myocardial protein levels of Shh, Patched-1 (Ptc1), and glioma-associated oncogene-1 (Gli1) were assessed.
  • Mice underwent sham surgery or myocardial infarction, followed by treatment with Shh pathway agonist or antagonist.

Main Results:

  • Type 1 diabetic mice exhibited decreased myocardial Shh, Ptc1, and Gli1 proteins, correlating with cardiac dysfunction.
  • MI induced Shh pathway activation in control mice but suppressed it in diabetic mice.
  • Shh pathway agonist treatment improved cardiac function, enhanced capillary density, and reduced infarct size in diabetic mice with MI.
  • Shh pathway antagonist treatment exacerbated cardiac dysfunction and infarct size in control mice with MI.

Conclusions:

  • The myocardial Shh pathway is impaired in type 1 diabetic mice.
  • This impairment contributes significantly to cardiac dysfunction following myocardial infarction.
  • Therapeutic strategies targeting Shh pathway augmentation may offer a novel approach for treating diabetic cardiac dysfunction.
Abstract

Related Concept Videos

Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Hedgehog Signaling Pathway02:33

Hedgehog Signaling Pathway

The Hedgehog gene (Hh) was first discovered due to its control of the growth of disorganized, hair-like bristles phenotype in Drosophila, much like hedgehog spines. Hh plays a crucial role in the development of organs and the maintenance of homeostasis in both invertebrates and vertebrates. However, while Drosophila has only one Hh protein, mammals have multiple functional Hedgehog proteins - Sonic (Shh), Desert (Dhh), and Indian Hedgehog (Ihh). All of these homologous proteins have adapted to...